Progressive renal insufficiency related to ALK inhibitor, alectinib

Alectinib is a second generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor and is generally effective and tolerated in patients who have demonstrated disease progression or adverse effects while on the first generation inhibitor, crizotinib. ALK inhibitors can cause a reversible chr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Kojiro, Ono, Hiroyuki, Matsuura, Motokazu, Hann, Michael, Ueda, Sayo, Yoshimoto, Sakiya, Tamaki, Masanori, Murakami, Taichi, Abe, Hideharu, Ishikura, Hisashi, Doi, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915949/
https://www.ncbi.nlm.nih.gov/pubmed/29713488
http://dx.doi.org/10.1093/omcr/omy009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915949/
https://www.ncbi.nlm.nih.gov/pubmed/29713488
http://dx.doi.org/10.1093/omcr/omy009

Ejemplares similares